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ABSTRACT  
Adhesion G-protein coupled receptors (aGPCRs) are emerging as important actors in energy 
homeostasis. Recent biochemical and functional studies using transgenic mice indicate that 
aGPCRs play important roles in endocrine and metabolic functions including -cell 
differentiation, insulin secretion, adipogenesis and whole body fuel homeostasis. Most 
aGPCRs are orphans, for which endogenous ligands have not yet been identified, and many 
of the endogenous ligands of the already de-orphanised aGPCRs are components of the 
extracellular matrix (ECM). In this review we focus on aGPCR expression in metabolically 
active tissues, their activation by ECM proteins, and current knowledge of their potential roles 
in islet development, insulin secretion, adipogenesis and muscle function.  
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Abbreviations: GPCRs - G-protein coupled receptors, aGPCRs - adhesion G-protein coupled 
receptors, T2D - type 2 diabetes, 1D - type 1 diabetes, ECM - extracellular matrix, GPS - 
GPCR proteolytic site, GAIN - GPCR autoproteolysis-inducing, WAT – white adipose tissue, 
BAT – brown adipose tissue, HGP – hepatic glucose production, GCGR – glucagon receptor  
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1. Introduction 
Type 2 diabetes (T2D), a state of persistently elevated blood glucose that is associated with 
long term damage to multiple organs, is a chronic metabolic disorder that poses considerable 
economic and health challenges to individuals and society. The global rise in T2D prevalence 
is mainly driven by the increased incidence in obesity: in 2016 over 650 million adults were 
obese (WHO, 2016), approximately 425 million of whom have diabetes (IDF, 2017). The global 
incidence of T2D is predicted to continue to rise as a consequence of changing demographics 
and increases in the number of people adopting a sedentary lifestyle. It is therefore essential 
that effective pharmacotherapies are available to people with T2D to ensure appropriate blood 
glucose control and thus minimise the complications associated with uncontrolled 
hyperglycaemia. 
 
1.1 Islet GPCRs as drug targets for type 2 diabetes 
GPCRs are the largest class of plasma membrane proteins, and they control many 
physiological processes through transducing a diverse array of signals to the cell interior 
through coupling to a family of heterotrimeric GTP-binding proteins. GPCRs were initially 
classified, based on their sequence similarities, into six alphabetically-named classes: Class 
A (rhodopsin-like receptors), Class B (secretin receptors), Class C (metabotropic glutamate 
receptors), Class D (fungal receptors), Class E (cyclic AMP receptors) and Class F (frizzled 
receptors). Of these, only classes A, B, C and F are found in vertebrates (Kolakowski, 1994). 
However, this classification did not take into account the subtle differences between the 
GPCRs within the same group and an alternative system was proposed that related GPCR 
structures to their functions and ligand preference. This alternative classification, known as 
the GRAFS system, sub-divides the GPCR superfamily into five classes: Glutamate, 
Rhodopsin, Adhesion, Frizzled and Secretin (Fredriksson et al., 2003; Alexander et al., 2017). 
Although progress has been made in identifying cognate ligands for the GPCRs, 121 out of 
the ~350 non-sensory GPCRs are still orphans, for which no activating ligands have been 
identified (Alexander et al., 2017). The rhodopsin family, which is the most studied, has 197 
receptors with known ligands and about 87 of them are orphans. The frizzled family consists 
of 11 receptors, all of which have been de-orphanised. Of the 33 adhesion GPCRs, only 6 
have been proposed to have an endogenous ligand (Davenport et al., 2013; Alexander et al., 
2017).  
 
Nearly 300 GPCRs, belonging to all classes of the GRAFS system, are expressed by human 
islets of Langerhans (Amisten et al., 2013). The function of many of these receptors has not 
yet been established, but it is known that numerous islet GPCRs play important roles in 
regulating growth, differentiation, secretion, maturation and survival of islet cells (Ahrén, 2009; 
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Amisten et al., 2013). As islets are crucial in maintaining glucose homeostasis through 
secretion of gluco-regulatory hormones, the importance of GPCR ligands in maintaining 
appropriate islet function has led to GPCRs being considered as attractive targets for novel 
T2D therapies. They have readily accessible druggable sites and are the targets of at least 
30% of all prescription drugs in current use (Santos et al., 2017; Sriram and Insel, 2018), which 
explains why pharmaceutical industries are investing heavily in them for new drug leads 
(Hauser et al., 2017; Persaud, 2017). 
 
GPCRs exert their effects via activation and release of the G-subunit from the heterotrimeric 
G-protein complex, although G-protein-independent effects via -arrestins have been 
described (Tuteja, 2009; Ravier et al., 2014; Smith and Rajagopal, 2016). The coupling 
preference of GPCRs to the G subtypes, Gi, Gs, Gq/11 and G12/13, determines their effects 
on insulin secretion. Generally, GPCRs that signal via Gs or Gq/11 increase insulin secretion 
through the generation of cAMP and IP3/DAG respectively, while signalling via Gi-mediated 
reductions in cAMP inhibits insulin release. The roles of -cell receptors coupled to G12/13 are 
not fully understood, but actin cytoskeleton remodelling and activation of Rho-associated 
protein kinase downstream of these GPCRs is likely to be coupled to increased insulin 
secretion. Islet-expressed GPCRs that have received considerable attention for diabetes 
therapy include GLP-1R, GPR40, GPR119 and GPR120 (Persaud, 2017). Drugs that activate 
GLP-1R have been in use for the clinical management of T2D for the past 10-15 years, and 
those targeting GPR40, GPR119 and GPR120 are either currently undergoing clinical trials or 
have been discontinued due to lack of efficacy or for safety reasons. Recently, a novel GLP-
1/GIP dual agonist, LY3298176, has shown very promising results in phase 2 trials in patients 
with T2D (Frias et al., 2018). 
 
2. Adhesion GPCRs 
The adhesion GPCR family consists of 33 members, with nine distinct subclasses (Hamann 
et al., 2015). A unified nomenclature was recently recommended for aGPCRs using the prefix 
ADGR, for adhesion G-protein coupled receptor, followed by a single letter and a number 
derived from their previous subfamily name and members within each subfamily, respectively 
(Table 1). In addition to the canonical seven transmembrane segments common to other 
GPCRs, aGPCRs have an extended N-terminal segment and they undergo self-cleavage 
during maturation at the GPCR proteolytic site (GPS) within the GPCR autoproteolysis-
inducing (GAIN) domain (Figure 1). The GAIN domain is a unique evolutionarily conserved 
structure of aGPCRs that is required for self-cleavage (Prömel et al., 2013). The N and C 
termini re-associate upon maturation and remain non-covalently attached to each other at the 
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GPS. The capacity of the N-terminal fragment of an aGPCR to cross-assemble with the C-
terminus of a different aGPCR and vice versa, and the ability of a small proportion of the N-
terminal segment, anchored independently to the cell membrane, to initiate downstream 
signalling upon ligand binding, increases the complexity of aGPCR heterodimer signalling 
considerably (Volynski et al., 2004; Silva et al., 2009; Huang et al., 2018). The GPS is found 
immediately upstream of the first transmembrane loop of aGPCRs and it is rich in cysteine 
residues, alternating with tryptophan in a C-W-W-C-C conserved sequence (Araç et al., 2012). 
The exceptions to this general aGPCR structure is GPR123, which does not have a GAIN 
domain, and GPR111, GPR114, GPR115 and CELSR1, which do not have cleavable GAIN 
domains (Araç et al., 2012; Krishnan et al., 2016; Wilde et al., 2016). Other aGPCRs that are 
predicted to have a non-cleavable GAIN domain include GPR124, GPR125, EMR1 and 
CELSR3, but this atypical structural feature has not yet been demonstrated (Hamann et al., 
2015).  
 
The extracellular N-termini of aGPCRs vary greatly in length and contain mucin-like motifs, 
which are thought to help them in their cell adhesion and cell-matrix interactions (Langenhan 
et al., 2013). They also contain multiple functional domains such as hormone binding domains, 
thrombospondin repeats, epidermal growth factor-calcium binding domain, and cadherin 
repeats (Bjarnadóttir et al., 2004; Hamann et al., 2015). The CELSR family members 
(CELSR1, CELSR 2, CELSR 3), which are associated with planar cell polarity in epithelial 
cells, contain four functional domains including several cadherin repeats on the uppermost 
part of their N-terminal segments (Wang et al., 2014), enabling them to participate in diverse 
physiological processes. 
 
Most aGPCRs are widely expressed in tissues such as the reproductive tract, neurons, 
stomach, lungs and various tumour cells, where they play roles in angiogenesis, cell adhesion, 
immune recognition and neuronal migration (Simundza and Cowin, 2013). However, some 
aGPCRs have fairly restricted tissue expression. For example, GPR123, BAI1, BAI3 and 
VLGR1 have biased expression in the brain, GPR111, GPR112, GPR128 in the 
gastrointestinal tract and GPR110 in the kidney (Fagerberg et al., 2014), suggesting that these 
receptors have particular functional capacities in those organs. Inactivating mutations in 
aGPCRs have been linked to several human diseases including bilateral frontoparietal 
polymicrogyria (Piao et al., 2004), vibratory urticaria (Boyden et al., 2016) and Usher 
syndrome type IIc (Weston et al., 2004), further pointing to the importance of aGPCRs in 
physiological processes and disease.   
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2.1 Adhesion GPCR activation and signalling  
As mentioned above, the N-terminal fragment of most mature adhesion GPCRs attaches non-
covalently with the membrane bound C-terminal fragment at the GPS, and the cleavage of the 
N-terminus has been suggested to modulate receptor activity. Removal of the N-terminal 
domains in GPR56, CD97 and BAI1 mutants has been associated with increased receptor 
activities (Paavola et al., 2011; Ward et al., 2011; Stephenson et al., 2013), which led to the 
proposal that the extracellular domain of aGPCRs acts as an inverse agonist of constitutive 
signalling. It is now established that removal of the N-terminus, either by ligand binding or 
mechanical detachment, is sufficient for receptor activation (Liebscher and Schöneberg, 
2016). Another signalling mechanism has been proposed based on the observation that a part 
of the aGPCR extracellular domain called a stachel sequence, which is buried in the GAIN 
segment, acts as a tethered agonist and this is exposed to the seven transmembrane domain 
upon ligand binding. This scenario has been demonstrated in a number of aGPCRs including 
GPR56, GPR64, GPR114, GPR126 and GPR133 (Wilde et al., 2016; Stoveken et al., 2015; 
Liebscher et al., 2014; Demberg et al., 2015; Kishore et al., 2016; Stoveken et al., 2017). Due 
to high sequence conservation of the aGPCR stachel region, stachel-derived peptides for a 
given receptor may be able to activate other aGPCRs within and beyond the same sub-family 
(Demberg et al., 2017). A further aGPCR activation mechanism has been identified through 
the observation that increased GPR126 signalling occurred when shaking forces were applied 
in the presence of the activating ligand laminin-211, presumably as a consequence of 
detachment of the N-terminal fragment and exposure of the stachel sequence (Petersen et 
al., 2015). It is therefore likely that aGPCRs are activated in a tripartite manner in vivo, such 
that binding of the endogenous ligand coupled with mechanical force from cell movement 
exposes the tethered agonist to initiate receptor activation (Figure 2).  
 
The hybrid and enigmatic structural features of aGPCRs have impeded understanding of their 
signalling mechanisms, and progress has been further limited by more than two-thirds of 
aGPCRs being orphan receptors. The major endogenous ligands reported so far for the de-
orphanised aGPCRs are components of the extracellular matrix (ECM), a meshwork of 
collagens, laminins and chondroitin sulphate proteoglycans that contains secreted proteins 
such as cytokines and growth factors trapped within it (Table 1). CELSR2 and 3 have no 
known ligands but are activated by N-terminal homophilic interactions (Shima et al., 2007). 
 
It has been postulated that aGPCRs will have multiple interacting ligands due to their unusually 
long N-terminal segment with adhesive motifs, and their broad expression in many tissues 
(Paavola and Hall, 2012). Four binding partners have been identified for the most studied 
aGPCR, GPR56: the ECM protein collagen III in the developing brain (Luo et al., 2011), the 
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cross-linking enzyme transglutaminase 2 (TG2) in HEK293 cells (Xu et al., 2006), the anti-
coagulant heparin in A375 melanoma cells (Chiang et al., 2016) and the stomach prohormone 
progastrin in colorectal cancer cells (Jin et al., 2017). Whereas activation of GPR56 by 
collagen III or an antibody directed against its N-terminal has been shown to couple to RhoA 
through G12/13 (Iguchi et al., 2008; Luo et al., 2011, 2014), recruitment of downstream 
signalling has not been demonstrated so far for TG2, heparin or progastrin, suggesting that 
collagen III is the main endogenous agonist of GPR56. Complexes between GPR56 and the 
tetraspanins CD9 and CD81 that couple to Gq have also been reported (Little et al., 2004), 
but there is currently no information on whether these complexes perform a physiological 
function.  
 
Another mechanism that might regulate signalling downstream of GPR56 is the generation of 
splice variants in cells expressing this receptor. Full length GPR56 consists of 13 exons, 
yielding proteins of 693 and 697 amino acids in human and mouse, respectively, and human 
GPR56 is known to undergo alternative splicing at exons 2, 3 and 10 to produce four isoforms 
termed GPR56687, GPR56692, GPR56523 and GPR56518 (Kim et al., 2010). Analysis of gene 
promoter activities in cells expressing GPR56 splice variants indicated that GPR56687 and 
GPR56692 increased serum response element (SRE) transcriptional activity, which may have 
been a consequence of deletion of six amino acids in the first intracellular loop contributing to 
enhanced G12/13/RhoA signalling (Kim et al., 2010). It has also been identified that the 
GPR56518 variant, in which a frameshift deletion causes a new translation start site, has 
increased basal activity and it has been predicted that alternative splicing of GPR56 could 
diversify functionality (Salzman et al., 2016). GPR56 is not the only aGPCR that undergoes 
alternative splicing: functional splice variants have been identified in all other aGPCRs except 
for GPR111, GPR115, GPR128, GPR144, BAI3, CELSR1, ELTD1 and VLGR1 (Bjarnadóttir 
et al., 2007). 
 
3. Function of adhesion GPCRs in metabolism 
Quantitative trait loci analyses have revealed that the majority of human aGPCRs are 
associated with traits involved in metabolism such as body weight and body fat, and leptin, 
glucose and insulin levels (Kovacs and Schöneberg, 2016). Adhesion GPCRs have been 
detected in metabolically active tissues such as islets, liver, skeletal muscle and adipose tissue 
(Figure 3), and TG2, a putative GPR56 interacting partner, was identified as a candidate gene 
for maturity onset diabetes of the young (Porzio et al., 2007).  
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3.1. Islets 
Most aGPCRs are expressed at varying levels in islets, with GPR56 being the most highly 
expressed GPCR in both mouse and human islets, and ELTD1, CELSR and latrophilin family 
members showing moderate expression (Table 1). Both mouse and human islets express 
readily quantifiable levels of the latrophilins LPHN1 and LPHN2,  but LPHN3 mRNA is of low 
abundance in mouse islets and undetectable in human islets (Amisten et al., 2017). Therefore, 
if latrophilins have any translational value in regulating islet function focus should be limited to 
LPHN1 and LPHN2. Research to date on the role played by adhesion receptors in islets has 
largely focused on their interaction with the ECM, and their roles in -cell development and 
insulin secretion. 
3.1.1 The extracellular matrix and -cell function 
Islets of Langerhans are surrounded by a capsule of ECM, made up of the peri-insular 
basement membrane (BM) and a subjacent interstitial matrix, and this is among the first 
structures to be destroyed by auto-immune assault in type 1 diabetes (Winer et al., 2003; 
Irving-Rodgers et al., 2008; Korpos et al., 2013). The functional significance of the ECM in 
normal islet function is well reported. Thus, ECM proteins are involved in a wide range of 
functions such as protecting -cells from apoptosis, enhancing insulin secretion, -cell 
migration and adhesion, and they play a role in pancreas development (Davis et al., 2012; 
Kaido et al., 2004; Huang et al., 2011; Shih et al., 2016; Arzouni et al., 2017; Llacua et al., 
2018; Olaniru et al., 2018a).  
 
A substantial amount of ECM is also distributed throughout the islet interior as the perivascular 
basement membrane that is associated with, and largely generated by, the microvasculature 
endothelium (Otonkoski et al., 2008). Unlike mouse islets, which have a single BM, the blood 
vessels of human islets have a duplex BM consisting of an outer parenchyma BM and an inner 
capillary BM (Virtanen et al., 2008), and this is speculated to provide extra protection against 
autoimmune insulitis (Otonkoski et al., 2008). The majority of -cells are in contact with the 
BM at the vasculature (Peiris et al., 2014) and it is becoming apparent that insulin granule 
fusion is enriched at points where -cells are in contact with the vascular BM (Low et al., 2014; 
Gan et al., 2018). In this way the ECM plays an important role in optimal insulin exocytosis by 
allowing targeted insulin secretion towards the vasculature. 
 
Receptors mediating cell-ECM interactions have been identified, but their functions and 
signalling mechanisms are not fully understood. It is known that signals arising from ECM 
proteins can be transmitted into -cells via membrane-localised adhesion receptors such as 
integrins, cadherins and aGPCRs, with integrin-mediated signalling cascades being the most 
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studied (Olaniru and Persaud, 2018). Efforts to translate integrin--cell-ECM interactions to 
T2D therapies have made little progress due to the sheer complexity of integrin/ECM 
interactions and non-specificity of ligand binding. However, given that GPCR family members 
have been successful in drug development, aGPCRs may prove more tractable than integrins 
in translating our understanding of -cell-ECM interaction into novel therapeutic targets, 
although much research needs to be carried out in this area. 
 
3.1.2 Islet development 
Islet development starts as early as embryonic day 9 (E9) in mouse and occurs in two phases. 
The first phase, which is also known as primary transition, takes place between E9 and E12.5 
and at this stage most of the cells are multipotent progenitor cells (MPCs) (Shih et al., 2013). 
As the nascent pancreas enlarges and buds the MPCs, marked by their expression of 
transcription factors such as Pdx1, Ptf1a, Nkx2.2 and Sox9, undergo extensive proliferation 
(Bastidas-Ponce et al., 2017). Towards the end of the primary transition, the first wave of 
differentiation begins, with the majority of the differentiated cells being glucagon-expressing 
-cells (Johansson et al., 2007). After E12.5, substantial differentiation occurs, giving rise to 
all of the endocrine cell types, with appearance of -cells, followed by -cells and then 
pancreatic polypeptide cells (Johansson et al., 2007). This is known as phase II or secondary 
transition (Jensen, 2004). As the mouse matures, islet cells migrate from the epithelium to 
form clusters and they do not resemble the adult islet structure until E18.5 (Villasenor et al., 
2008). Some differences in human islet development have been reported, such as in the 
presence of a single wave of endocrine differentiation, delayed expression of key 
differentiation genes and the islet cytoarchitecture (Nair and Hebrok, 2015). Thus, at 30 days 
post-conception (dpc) in human pancreas the MPCs express key transcription factors such as 
Pdx1, Ptf1a, Sox9, Gata4 and Nkx6.1 but not Nkx2.2, which is only detectable after endocrine 
cell commitment at 10 weeks post-conception (wpc) (Jennings et al., 2013). Also, in humans 
insulin-positive -cells are the first endocrine cells to appear (at 8wpc), rather than the -cells 
that are observed first in developing mouse pancreas (Jeon et al., 2009; Salisbury et al., 2014). 
In addition, approximately 30% of the early human pancreas endocrine cells express more 
than one hormone, as the MPCs differentiate to other endocrine cell types, whereas the 
appearance of polyhormonal cells in mouse islets is scarce (Herrera, 2000; Riedel et al., 
2012). Despite these species-specific differences in endocrine pancreas specification the 
transcription factors regulating pancreas development are common to mice and humans and 
the overall islet structure is similar.  
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There is increasing evidence implicating ECM proteins and aGPCRs in pancreas 
development. It is now thought that ECM components provide cues for cells to migrate during 
organ development (Langenhan et al., 2016), govern cell fate decisions of bipotent pancreatic 
progenitors to follow either duct or endocrine lineages (Mamidi et al., 2018), and they regulate 
branching morphogenesis during pancreas development (Shih et al., 2016). GPR56 is highly 
expressed in NGN3+ endocrine progenitors in the developing pancreas (Gu et al., 2004), but 
its function in islet development is not yet known. Studies in neuronal and seminiferous tubule 
development in mice have indicated that GPR56 is critical for proper formation of the 
cerebellum, as it allows the developing neurons to adhere to the ECM of the pial basement 
membrane (Li et al., 2008; Luo et al., 2011), and its absence during embryogenesis leads to 
reduced male fertility (Chen et al., 2010). Considering the high expression of GPR56 in the 
developing pancreas it may play a role in islet formation, and our preliminary studies showing 
fewer -cells and more -cells in islets from neonatal GPR56 null mice support this (Olaniru 
et al., 2018b). In addition, it has been established that CELSR3 is critical for islet development, 
as mice with pancreatic progenitor Pdx1-specific deletion of CELSR3 are glucose intolerant in 
adult life, as a result of severe islet -cell differentiation deficiency (Cortijo et al., 2012). 
 
3.1.3 Insulin secretion  
Insulin release from islet -cells is a tightly controlled process that is mainly regulated by 
nutrient availability and feedback communication between heterogenous islet cells and insulin-
sensitive tissues. Although the contribution of classical GPCRs, such as GLP-1R, M3 
muscarinic receptors and 2-adrenergic receptors (2-AR), to glucose-induced insulin 
secretion is well established (Ahrén, 2009; Kong et al., 2010; Santulli et al., 2012), the 
involvement of aGPCRs is only just starting to be appreciated. In our screen of all GPCRs 
expressed by human islets, we detected 22 of the 33 known aGPCRs, including GPR56, 
GPR116, latrophilins (LPHNs), BAI3, ELTD1 and CELSR family members (Amisten et al., 
2013), and recent studies are beginning to reveal the effects of individual aGPCRs on islet 
secretory function.  
 
Our observation that GPR56 is the most abundant GPCR in human and mouse islets (Amisten 
et al., 2013, 2017) is consistent with its previously reported high expression in mouse pancreas 
(Haitina et al., 2008). Collagen III, the endogenous ligand of GPR56 (Luo et al., 2011), 
activates the receptor in a Gα12/13/RhoA dependent manner (Iguchi et al., 2008; Luo et al., 
2014). In the islets, collagen III is not expressed by the -cells but by the vascular endothelial 
cells within the islets and the basement membrane (Van Deijnen et al., 1994; Olaniruet al., 
2018a). Exposure of islets and -cells to exogenous collagen III potentiates glucose-mediated 
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insulin secretion and protects them from apoptosis, in a GPR56-dependent manner (Dunér et 
al., 2016; Olaniru, et al., 2018a), demonstrating that islets use -cell-expressed GPR56 to 
sense signals from ECM collagen III to improve -cell mass and secretory function. Consistent 
with this, islets in which GPR56 expression was acutely downregulated with siRNA had less 
insulin content and reduced insulin secretory capacity (Dunér et al., 2016). However, GPR56 
knockout mice are normal and are able to regulate blood glucose levels appropriately, and 
islets isolated from them respond appropriately to glucose (Olaniru et al., 2018a). In contrast, 
deletion of TG2, which is thought to be a GPR56 binding partner, resulted in glucose 
intolerance in mice and islets isolated from them showed reduced glucose-induced insulin 
secretion, although signalling via GPR56 was not explored as TG2 had not yet been identified 
as a GPR56 activating ligand (Bernassola et al., 2002). This role for TG2 in regulating blood 
glucose levels via stimulation of insulin release could not be replicated in a separate study 
where deletion or constitutive activation of TG2 did not affect islet insulin secretory responses 
to glucose or whole body glucose homeostasis (Iismaa et al., 2013).  
 
The black widow spider neurotoxin, -latrotoxin, was shown to induce exocytotic release of 
insulin from clonal -cells that expressed latrophilin, and transient overexpression of latrophilin 
in a -cell line with low endogenous latrophilin expression conferred insulin secretory 
responsiveness to -latrotoxin in those cells (Lang et al., 1998). It was proposed that this 
stimulatory effect of -latrotoxin may have been a consequence of it mimicking a natural ligand 
of the latrophilin receptor, but it is not yet known whether specific LPHN activation in islets is 
coupled to increased insulin secretion since LPHNs are still classified as orphans for which 
endogenous ligands have not yet been defined. Fibronectin leucine rich transmembrane 
proteins (FLRT) (O’Sullivan et al., 2012) and teneurins (Silva et al., 2011; Boucard et al., 2014) 
have been proposed as endogenous binding partners for LPHNs, but nothing is known about 
the effects of these proteins on islet function. 
 
Less is known about aGPCR signal transduction mechanisms than for the other GPCR 
families, most likely because most of them are orphans. However, there is evidence of aGPCR  
signalling via both stimulatory Gs and inhibitory Gi coupling (Hamann et al., 2015), so it 
might be expected that they could have inhibitory as well as stimulatory effects on insulin 
secretion. In this context, it has recently been reported that the secreted protein, complement 
1q like-3 (C1ql3), which has been identified as an activating ligand for BAI3 (Bolliger et al., 
2011; Hamoud et al., 2018), decreased glucose-induced insulin secretion from mouse and 
human islets in a BAI3-dependent manner by inhibiting cAMP production (Gupta et al., 2018). 
These data were generated using C1ql3 present in conditioned medium from HEK293 cells 
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transfected with a C1ql3 plasmid, so it would be useful to identify whether similar results are 
also obtained with exposure of islets to recombinant C1ql3. A related C1q domain-containing 
protein, C1ql4, has recently been identified as an inhibitor of BaI3 while stabilin-2 is an 
activator. It is thought that the relative expression of these two BaI3 binding partners is 
important in the regulation of myoblast fusion (Hamoud et al., 2018), but there is currently no 
information on BaI3 regulation by C1ql4 or stabilin-2 in islets. 
 
3.2 Adipose tissue  
The traditional function of adipose tissue is to store energy and release it in the form of fatty 
acids when required, but it is now accepted it plays an important role as an endocrine organ 
that secretes a range of adipokines that are critical for maintaining whole body energy 
homeostasis. The major adipokine secreted by WAT is leptin, which is involved in metabolic 
regulation through its anorexigenic effects to inhibit food intake (Friedman, 2016). There is an 
imbalance in adipokine expression in obesity, with adipocyte hypertrophy leading to up-
regulation of pro-inflammatory adipokines (e.g. IL-6, leptin, resistin and TNF) and 
concomitant reductions in anti-inflammatory adipokines (e.g. adiponectin, adipolin and 
omentin-1) (Ohashi et al., 2014; Nakamura et al., 2014). This chronic, low-grade inflammatory 
environment in obesity contributes to cardiovascular and metabolic disorders (Nakamura et 
al., 2014).  
 
Adipose tissue is generally sub-classified as white adipose tissue (WAT) and brown adipose 
tissue (BAT). In addition, beige or brite adipocytes with brown-like properties have been found 
in WAT depots (Wu et al., 2012), and it is now generally accepted that these arise from 
browning of WAT rather than being a distinct type of adipocyte. WAT is the primary energy 
storage organ that expands and contracts under conditions of energy excess and deficit, 
respectively. BAT is mainly found in neonates and infants where it has an essential function 
to generate non-shivering heat during cold exposure. Adipocytes in BAT have many 
mitochondria with high expression of uncoupling protein 1 (UCP-1), allowing them to efficiently 
convert lipids into heat, and BAT deficiency in mice is associated with obesity, insulin 
resistance and reduced thermogenic ability (Lowell et al., 1993; Hamann et al., 1998). It has 
been calculated that 40-50g of maximally activated BAT in adult humans could account for 
20% of total energy expended (Rothwell and Stock, 1983), and the importance of BAT in 
energy metabolism has heightened the search for BAT activators for use as obesity and T2D 
therapies (Scheideler et al., 2017). 
 
Human subcutaneous WAT and mouse mature BAT express over 150 and 230 GPCRs, 
respectively (Amisten et al., 2015; Klepac et al., 2016). In terms of aGPCRs, GPR56, GPR116, 
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GPR124 and ELTD1 are highly expressed in human subcutaneous adipose tissue (Amisten 
et al., 2015; Figure 3) and profiling of mouse brown adipose tissue has indicated relatively 
high expression of GPR124, GPR125, GPR133, LPHN1 and LPHN2 (Klepac et al., 2016). 
Research on the role of GPCRs in adipose tissue has largely focused on -adrenergic receptor 
signalling, with observations that selective activation of 3 receptors in BAT and WAT was 
associated with increased energy expenditure and reduced food intake in mice (Grujic et al., 
1997). However, the enthusiasm for a 3 adrenergic receptor-directed therapy was diminished 
in human studies due to lack of agonist efficacy and undesirable side effects (Poekes et al., 
2015).  
 
Studies have been performed to identify the role of GPR116 in white adipocyte differentiation 
and whole body glucose homeostasis. It was found that depletion of GPR116 in pre-
adipocytes in vitro impaired their capacity to differentiate to mature adipocytes (Nie et al., 
2012). In addition, adipose tissue-specific deletion of GPR116 produced mice that were 
glucose intolerant and insulin resistant, which was exacerbated by high fat feeding (Nie et al., 
2012), suggesting that if ligands are identified that selectively activate GPR116 they could be 
useful therapeutically in normalising glucose homeostasis.  
 
The recent profiling of the BAT GPCRome (Klepac et al., 2016) has led to renewed interest in 
the possibility of targeting BAT GPCRs to combat obesity. In particular, in that study it was 
identified that antagonising Gq signalling could provide a mechanism for increasing brown 
and beige adipocyte number, and this is a potential strategy for increasing energy expenditure 
in obesity. In addition, since aGPCRs are the second most abundant family of GPCRs (after 
the large rhodopsin receptor family) in BAT, and there are altered expression profiles of 
aGPCRs upon differentiation of pre-adipocytes to mature brown adipocytes (Klepac et al., 
2016) there is strong rationale for research exploring aGPCR function in BAT. CELSR2 is 
down-regulated in mature brown adipocytes (Klepac et al., 2016) and the potential importance 
of this aGPCR in metabolic control is indicated by the correlation of single nucleotide 
polymorphisms in CELSR2 with altered low-density lipoprotein levels in humans (Kathiresan 
et al., 2008). The roles of aGPCRs that show altered expression during brown adipocyte 
maturation will provide important information on whether they may be targeted therapeutically, 
but as with identifying aGPCR function in other metabolically active tissues progress is limited 
by the lack of suitable ligands for most of the receptors. 
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3.3 Skeletal muscle 
Skeletal muscle cells take up glucose following food intake through insulin-dependent 
translocation of GLUT4 transporters to the myocyte plasma membrane, and glucose that is 
not required for muscle activity is stored as glycogen (DeFronzo and Tripathy, 2009, Bradley 
et al., 2015). Glucose transport into myocytes can also occur in an insulin-independent manner 
through exercise-induced muscle contractility (Sinacore and Gulve, 1993), thus ensuring that 
myocytes obtain an appropriate fuel supply in the post-absorptive state. The insulin resistance 
that commonly occurs in obesity, T2D, and other cardiometabolic disorders impairs insulin-
mediated glucose uptake via GLUT4 and it is now apparent that 2 adrenergic receptor 
activation can promote glucose uptake into skeletal muscle (Sato et al., 2014). This increase 
in glucose clearance is dependent on GLUT4 translocation, but occurs independently of the 
insulin-mediated signal transduction cascade, offering the potential of circumventing myocyte 
insulin resistance.  
 
The possibility of targeting aGPCRs to treat muscle disease through promoting skeletal 
muscle cell growth has been raised recently (White, 2016), and there is an increasing body of 
evidence indicating that aGPCRs are crucial for myoblast differentiation and muscle mass 
regulation. The majority of aGPCR family members that have been detected in human skeletal 
muscle are expressed at low levels (GPR56, GPR64, GPR113, CD97, BAI3, CELSR2, and 
ELTD1), and GPR116 and GPR125 are reported to have moderate expression (Jean-Baptiste 
et al., 2005; Duff et al., 2015).  
 
Cell-cell fusion of myoblasts is a crucial and tightly regulated process in muscle formation and 
repair (Rochlin et al., 2010). By interacting with the conserved ELMO-DOCK1-Rac pathway, 
BAI3 is obligatory for myoblast fusion in myogenesis and in adult muscle regeneration 
(Hamoud et al., 2014). BAI3 can either inhibit or promote myoblast fusion by binding to C1q-
like proteins or stabilin-2, respectively (Hamoud et al., 2018). In chicken embryos, a loss of 
function mutation in BAI3 blocked myoblast fusion, leading to reduced myofibre length 
(Hamoud et al., 2014), while BAI3 knockout mice have smaller muscle fibres that are less 
efficient in recovering from injury (Hamoud et al., 2018). It has been identified that GPR56 
expression is upregulated at the early stage of myoblast differentiation, and its deletion 
resulted in reduced myoblast fusion (Wu et al., 2013). However, no difference in muscle 
phenotype was observed in GPR56 knockout mice (Wu et al., 2013), suggesting that GPR56 
is not required for skeletal muscle development in vivo. A role for GPR56 in regulating muscle 
mass is supported by observations that it is up-regulated under conditions of excess load on 
skeletal muscle, that its overexpression in vitro leads to myocyte hypertrophy and that it 
regulates PGC-14-mediated muscle hypertrophy in vivo (White et al., 2014). Additionally, 
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GPR56 increases muscle hypertrophy via G12/13 signalling, with subsequent downstream 
activation of mTOR and IGF-1 leading to increased protein synthesis (White et al., 2014). The 
sarcoplasmic reticulum of myofibres from CD97 null mice have altered morphology, but this 
does not translate to any changes in muscle function and the authors concluded that its role 
is most likely associated with skeletal muscle differentiation (Zyryanova et al., 2014). Overall, 
aGPCRs are important players in muscle physiology and further research is required to identify 
whether they also play a role in contraction-induced glucose transport or other metabolic 
parameters in skeletal muscle. In this context it is of interest that CD97 mRNA upregulation 
has been implicated in the development of skeletal muscle insulin resistance (Poelkens et al., 
2013), but further work is required to determine if this is a causative relationship and whether 
myocyte aGPCRs could be targeted therapeutically to improve glucose homeostasis. 
 
 
3.4 Other metabolic tissues with potential for aGPCR function  
aGPCRs are expressed by other metabolic tissues such as liver, gastrointestinal tract and 
hypothalamus, but much less is known about their functions in these tissues than in islets, 
adipose tissue and skeletal muscle.  
3.4.1 Liver 
The liver plays a pivotal role in regulating glucose homeostasis by acting as a storage organ 
in the absorptive state and by maintaining glucose levels through glycogenolysis and 
gluconeogenesis during the post-absorptive state and fasting. Hepatocytes express many 
GPCRs, which are predicted to play important roles in liver function (Regard et al., 2008). The 
glucagon receptor (GCGR), a Gs-coupled GPCR, is one of the most studied hepatocyte 
receptors since it directly controls hepatic glucose production: when blood glucose levels are 
low glucagon is secreted from islet -cells and it increases liver glycogenolysis and 
gluconeogenesis through GCGR activation and generation of cAMP. This is an important 
physiological process, but it can be disrupted in T2D where reduced anabolic input from insulin 
and increased hepatic GCGR signalling can lead to excessive hepatic glucose production 
(HGP) (Lin and Accili, 2011). As Gi-coupled GPCRs inhibit cAMP production it has been 
proposed that they could be targeted therapeutically to combat the increased HGP that occurs 
in T2D. This has recently been investigated by a chemogenetic approach where mice 
expressing a Gi-coupled GPCR in their hepatocytes were exposed to a ligand that specifically 
activated that receptor, and the effects on glucose regulation in vivo and in vitro were 
evaluated (Rossi et al., 2018). Selective activation of Gi in mouse hepatocytes paradoxically 
led to increased HGP and impaired glucose homeostasis, indicating that this is not an 
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appropriate strategy for reducing glucose levels in T2D, most likely because antagonism of 
hepatocyte cAMP generation will have an impact on multiple processes in addition to blockade 
of HGP. The authors concluded that rather than activating hepatocyte Gi-coupled signalling 
it would be more appropriate to antagonise it for treating T2D, but it seems likely that a more 
nuanced approach will be necessary. 
 
The involvement of aGPCRs in hepatocyte function has not yet been described, but global 
transcriptomic analysis has revealed that multiple aGPCRs are expressed by human liver, with 
GPR125, GPR126, LPHN2 and CD97 showing high levels of expression, while GPR116, 
GPR124, GPR128 and ELTD1 were detected at moderate levels (Fagerberg et al., 2014). Our 
analysis of mouse liver has indicated a similar high expression pattern for GPR125 and 
LPHN2, and moderate expression of GPR116 and ELTD1 (Atanes and Persaud, 
unpublished). In contrast, while CD97 mRNA was highly expressed in human liver our 
quantifications indicated that it was expressed at low levels in mouse liver, as were GPR124 
and GPR126, while we could not detect GPR128 in mouse liver by qPCR. Human hepatocytes 
are available for research, but as rodent samples are often used as surrogates it is important 
that research is focused on those rodent aGPCRs that are also expressed by human 
hepatocytes so that data have high translation value. Further work is required to define the 
function of liver aGPCRs and whether they present an opportunity for therapeutic intervention 
to combat liver dysfunction that occurs in fatty liver disease and diabetes.  
3.4.2 Gastrointestinal tract  
The gastrointestinal (GI) tract is the largest endocrine organ in mammals. It is involved in 
various metabolic processes such as appetite regulation, digestion, nutrient absorption and 
potentiation of glucose-induced insulin secretion through the release of the incretins GLP-1 
and GIP from specialised enteroendocrine L cells. GLP-1 secretion is stimulated by activation 
of GPR40 and GPR119 by triacylglycerol metabolites and the bile acid GPCR, TGR5 (Hauge 
et al., 2017), and elevations in GLP-1 and PYY, another L cell-derived GPCR ligand, have 
been implicated in improved metabolic outcomes following bariatric surgery (Pucci and 
Batterham, 2018). The production of GPR119 agonists by human gastrointestinal bacteria has 
recently been associated with increased GLP-1 secretion and improved glucose tolerance in 
mice (Cohen et al., 2017). These observations indicate that there are additional physiological 
mechanisms regulating GLP-1 release, and open up the possibility that bacteria engineered 
to produce GPR119 ligands could have therapeutic potential to treat T2D. There has been 
interest from pharmaceutical companies to enhance the incretin response and ligands 
targeting a number of enteroendocrine cell-expressed GPCRs, including GLP-1R, GPR40, 
GPR119 and GPR120, are undergoing investigation as potential therapies for T2D (Mace et 
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al., 2015; Hoque et al., 2018). It has been reported that aGPCRs expressed in the GI tract 
include GPR56, GPR126, GPR128, CD97, LPHN2 and CELSR1 (Fagerberg et al., 2013; 
Hamman et al., 2015). However, the role, if any, that GI tract aGPCRs play in regulating fuel 
homeostasis is currently unknown and most studies to date have focused on their contribution 
to colorectal carcinoma (Hilbig et al., 2018; Ji et al., 2018). 
3.4.3 Hypothalamus 
The importance of the hypothalamus in many metabolic processes such as feeding and 
energy homeostasis is well known, and many of these functions are mediated via 
hypothalamic GPCRs for ligands such as neuropeptide Y, opioids, serotonin and -amino 
butyric acid (Qiu et al., 2006, 2007; Fu and van den Pol, 2010). The aGPCRs GPR56, GPR64, 
and VLGR1 are highly expressed in the hypothalamus (Liu et al., 1999; Haitina et al., 2008) 
and at least 23 aGPCRs have been detected in the arcuate nucleus, which is the metabolic 
centre of the hypothalamus (Rønnekleiv et al., 2014). Of the aGPCRs expressed in the arcuate 
nucleus, GPR56 and BAI1 are the most abundant (Rønnekleiv et al., 2014), but there is still 
no data available on whether these receptors or other arcuate nucleus aGPCRs are present 
on the NPY/AgRP or POMC/CART neurons that regulate food intake, or whether they may 
represent novel targets for appetite regulation in obesity. 
 
4 Conclusion and future directions 
Research defining the importance of aGPCRs in regulating appropriate energy homeostasis 
is still at an early stage, and considerable further research is required to determine whether 
members of this family of receptors may be suitable candidates for treating metabolic 
disorders such as obesity and T2D. Nonetheless, the expression of a wide range of aGPCRs 
by tissues important in ensuring that blood glucose levels are regulated within a tight range 
and the close association between aGPCRs and metabolic traits supports continued 
exploration of their utility as druggable targets. 
 
Figure 4 summarises some of the key information relating to aGPCR function in islet -cells, 
adipocytes and myocytes, and as aGPCR metabolic research progresses we will be able to 
build up a clearer picture of the key candidates that may have therapeutic potential. 
Nonetheless, there are still barriers to rapid progress in this field and future research will be 
greatly facilitated by de-orphanisation of the remaining aGPCRs and identification of specific 
small molecule agonists and antagonists. In addition, more studies are required to fully 
understand the signalling mechanisms downstream of aGPCR activation, and this too will be 
assisted by availability of highly selective ligands. Given their broad expression, it will also be 
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interesting to identify aGPCR splice variants that may be specifically targeted in metabolically 
active tissues without causing undesirable side effects.  
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Fig 1: Adhesion GPCR architecture.  
Adhesion GPCRs have unusually long extracellular N-terminal fragments (NTF) that contain 
several adhesive motifs, which are important in cell adhesion and cell-matrix interactions. The 
NTF is joined non-covalently to the C-terminal fragment at the GPCR proteolytic site (GPS) 
within the GPCR autoproteolysis-inducing (GAIN) domain. The stachel sequence is buried in 
the GAIN domain and is exposed upon ligand binding. 
 
Fig 2: Activation of aGPCRs.  
Dissociation of the N-terminal fragment from the C-terminal transmembrane domain is the 
main activation mechanism for most aGPCRs. Binding of activating ligands, which include the 
extracellular rmatrix proteins collagen III and laminin-211, leads to detachment of the N-
terminal fragment of cleavable aGPCRs from the C-terminal fragment at the GPS. This 
exposes a stachel sequence that induces tethered agonism and subsequent downstream 
signalling. The stachel sequence may also be exposed by mechanical force or cellular 
vibrations. Receptor activation is coupled to intracellular effects through coupling to members 
of the heterotrimeric GTP-binding protein family (Gs, Gi, Gq and G12/13). 
 
Fig 3: Expression pattern of aGPCRs in metabolically active tissues.  
The relative expression of aGPCR transcripts in human brain, liver, gastrointestinal tract, 
skeletal muscle, pancreas and adipose tissue are indicated as RPKM (reads per kilobase of 
transcript per million mapped reads). + = ≤1; ++ = 1-5; +++ = 5-10; ++++ = 10-15; >++++ = 
>15 RPKM. Data were obtained from published RNAseq analysis (Fagerberg et al., 2013). 
 
Fig 4: Schematic summary of the signalling pathways downstream of aGPCRs that have been 
implicated in metabolic cell development and function.  
a) CELSR3 promotes differentiation of pancreas endocrine progenitors to β-cells in mice via 
JNK activation and phosphorylation of c-jun. CELSR3 knockout mice have severe β-cell 
differentiation deficiency, which leads to glucose intolerance in adulthood. 
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b) Activation of a Gs-coupled aGPCR such as LPHN1 in β-cells increases cAMP generation, 
which promotes insulin exocytosis through activation of protein kinase A (PKA) and/or 
exchange proteins activated by cAMP (EPACs). Similarly, GPR56 activation by collagen III in 
-cells increases insulin secretion through Gq-mediated signalling. Conversely, activation of 
a Gi-coupled aGPCR such as BAI3 by its agonist C1lq3 inhibits insulin exocytosis by 
decreasing cAMP production.  
c) Deletion of GPR116 in pre-adipocytes in vitro impaired their capacity to differentiate into 
mature adipocytes, and GPR116 knockout mice are glucose intolerant and insulin resistant. 
d) BAI3 recruits the ELMO/DOCK1 complex in myoblasts, allowing their fusion to generate 
multinucleated myofibres during myogenesis. This function is differentially regulated by 
stabilin-2 and C1ql4 regulation of BAI3: whereas stabilin-2 activates BAI3, leading to coupling 
to Gi to promote myoblast fusion, C1ql4 inhibits it.  
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Table 1 
            
 Adhesion GPCR 
 
 
 
Expression in human 
 
Ligands or N-
terminal 
interactors 
 
Ligand action 
Metabolic 
phenotypes in KO 
mice 
Sub-
group  
Current 
nomenclature 
(previous 
nomenclature) 
Pancreas Islets    
I 
 
 
 
ADGRL1 (LPHN1) Yes Yes 
(+++) 
-latrotoxin   
ADGRL2 (LPHN2) Not 
detected 
Yes (+) -latrotoxin   
ADGRL3 (LPHN3) Yes Not 
detected 
Fibronectin 
leucine rich 
transmembrane 
protein 3 
  
ADGRL4 (ELTD1) Not 
detected 
Yes (++)    
II ADGRE1 (EMR1) Not 
detected 
Not 
detected 
   
ADGRE2 (EMR2) Not 
detected 
Yes (+) Chondroitin 
sulphatea 
  
ADGRE3 (EMR3) Not 
detected 
Not 
detected 
   
ADGRE4 (EMR4) Not 
detected 
Not 
detected 
   
ADGRE5 (CD97) Not 
detected 
Yes (+) CD55, 51 
integrin 
  
III ADGRA1 (GPR123) Not 
detected 
Yes (+)    
ADGRA2 (GPR124) Not 
detected 
Yes (+) Glycosamino-
glycansa 
  
ADGRA3 (GPR125) Yes Yes (+)    
IV ADGRC1 (CELSR1) Not 
detected 
Yes (+)    
ADGRC2 (CELSR2) Not 
detected 
Yes (+) N-terminal 
homophilic 
interaction 
 Normal endocrine cell 
differentiation (Cortijo 
et al., 2012) 
ADGRC3 (CELSR3) Not 
detected 
Yes (+) N-terminal 
homophilic 
interaction 
 Impaired -cell 
differentiation, glucose 
intolerance (Cortijo et 
al., 2012) 
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V ADGRD1 (GPR133) Yes Yes (+)    
ADGRD2 (GPR144) Not 
detected 
Not 
detected 
   
VI ADGRF1 (GPR110) Yes Not 
detected 
Synaptamide 
(Lee et al., 
2016) 
  
ADGRF2 (GPR111) Not 
detected 
Not 
detected 
   
ADGRF3 (GPR113) Not 
detected 
Yes (+)    
ADGRF4 (GPR115) Not 
detected 
Yes (+)    
ADGRF5 (GPR116) Not 
detected 
Yes (+)   Hyperlipidaemia, 
impaired glucose 
tolerance and insulin 
resistance, decreased 
adipocyte size (Nie et 
al., 2012) 
VII ADGRB1 (BAI1) Not 
detected 
Not 
detected 
Phosphatidyl-
serine, lipopoly-
saccharide, v5 
integrin, Nogo 
receptor-like 2 
and 3 (Chong et 
al, 2018) 
  
ADGRB2 (BAI2) Not 
detected 
Yes (+)    
ADGRB3 (BAI3) Not 
detected 
Yes (+) C1ql1 &3, 
stabilin-2 
(Hamoud et al., 
2018) 
↓ insulin secretion 
(Gupta et al., 
2018) 
 
VIII ADGRG1 (GPR56) Yes Yes 
(+++) 
Collagen IIIa,  
 
 
 
 
TG2a, heparin, 
progastrin 
↑ insulin secretion,  
↓ apoptosis 
(Dunér et al., 
2016; Olaniru et 
al., 2018a) 
Normal glucose 
homeostasis (Olaniru 
et al., 2018a) 
ADGRG2 (GPR64) Yes Not 
detected 
   
ADGRG3 (GPR97)  Not 
detected 
Yes (+)    
ADGRG4 (GPR112) Not 
detected 
Yes (+)    
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ADGRG5 (GPR114) Not 
detected 
Yes (+)    
ADGRG6 (GPR126) Not 
detected 
Yes (+) Collagen IVa, 
laminina, prion 
protein 
  
ADGRG7 (GPR128) Not 
detected 
Not 
detected 
   
IX ADGRV1 (VLGR1) Yes Not 
detected 
   
 
Table 1: Adhesion GPCR expression in human pancreas and islets.  
Expression of aGPCR proteins in human pancreas and islets is taken from immunohistochemistry 
data from the Human Protein Atlas Project, in which all antibodies were validated for sensitivity and 
reliability (www.proteinatlas.org/about/antibody+validation) (Uhlen et al., 2015). aGPCR mRNA 
expression in human islets is taken from qPCR and RNA-Seq data (Amisten et al., 2013; Uhlen et 
al., 2015).  
Key: Yes (+++): strongly expressed; Yes (++): moderately expressed; Yes (+): slightly expressed; 
Not detected: not detected or no available data, but not necessarily a proof of absence; blank cells: 
unknown or not yet investigated; a: endogenous ligands/binding partners of aGPCRs which are 
components of the ECM (Stacey et al., 2003; Vallon and Essler, 2006; Xu et al., 2006; Luo et al., 
2011; Paavola et al., 2014; Petersen et al., 2015). 
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